Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
- Author(s)
- Reynolds, GK; Sim, B; Spelman, T; Thomas, A; Longhitano, A; Anderson, MA; Thursky, K; Slavin, M; Teh, BW;
- Journal Title
- Critical Reviews in Oncology/Hematology
- Publication Type
- Review
- Abstract
- A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group.
- Publisher
- Elsevier
- Keywords
- Car-t; Cellular therapies; Infections; Lymphoma; Myeloma
- Department(s)
- Infectious Diseases; Health Services Research; Clinical Haematology
- PubMed ID
- 37739146
- Publisher's Version
- https://doi.org/10.1016/j.critrevonc.2023.104134
- Open Access at Publisher's Site
https://doi.org/10.1016/j.critrevonc.2023.104134- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-21 05:54:29
Last Modified: 2023-11-21 05:55:40